{"id":91578,"date":"2025-03-13T13:45:07","date_gmt":"2025-03-13T13:45:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/ennodc-presents-positive-phase-i-data-at-croi-2025-demonstrating-long-lasting-immunity-induced-by-antibody-mediated-vaccines-amvs\/"},"modified":"2025-03-13T13:45:07","modified_gmt":"2025-03-13T13:45:07","slug":"ennodc-presents-positive-phase-i-data-at-croi-2025-demonstrating-long-lasting-immunity-induced-by-antibody-mediated-vaccines-amvs","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/ennodc-presents-positive-phase-i-data-at-croi-2025-demonstrating-long-lasting-immunity-induced-by-antibody-mediated-vaccines-amvs\/","title":{"rendered":"EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)"},"content":{"rendered":"
\n

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)<\/strong><\/p>\n

Findings in HIV highlight AMV technology’s versatility, robust immune response, and excellent safety profile, underpinning company\u2019s expansion into oncology applications<\/strong><\/p>\n

Paris, France \u2013 March 13, 2025<\/strong> \u2013 EnnoDC, a clinical-stage immunotherapy biotech pioneering Antibody Mediated Vaccines (AMVs), today announced the presentation of final results from the ANRS VRI06 Phase I trial (NCT04842682) at the 2025 Conference on Retroviruses and Opportunistic Infections (#CROI2025, San Francisco, USA abstract #426). Presented by Prof. Yves Levy<\/strong>,1<\/sup> the data demonstrate the ability of CD40.HIVRI.Env (AMV.HIVRI) to induce controlled, durable and potent immune responses with an excellent safety profile in non-HIV infected volunteers, further validating the transformative potential of the AMV approach in infectious diseases and cancer.<\/p>\n

AMVs are a new class of immunotherapy that combines the targeted action of an immunomodulatory antibody with the long-lasting effect of a vaccine. Thanks to its head (a CD40 dendritic cell engager) and tail (a commutable antigen from virus or tumor), each AMV induces a specific, controlled and broad immune response.<\/p>\n

The ANRS VRI06 trial was the first in human clinical trial assessing the safety and immunogenicity of an AMV targeting the HIV envelope in non-HIV infected human volunteers.<\/p>\n

Results of the first phase of the ANRS VRI06 trial showed a good safety profile and strong immunogenicity of CD40.HIVRI.Env (AMV.HIVRI). These immune responses mobilized both antibody- and cell-mediated immunity and persisted until week 48, 6 months after the last boost (Y. Levy et al., EClinicalMedicine, 2024). The long-term follow-up of this study was aimed to evaluate the durability of these responses and the booster effect of a single new injection (late boost) of CD40.HIVRI.Env (AMV.HIVRI), with or without adjuvant. Results presented at the CROI 2025 demonstrated the durability of these responses in median 80 weeks after ANRS VRI06 study entry: a single boost of low dose, even un-adjuvanted, of the AMV was sufficient to extend these responses 6 months following the late boost.<\/p>\n

\u201cThese compelling results in HIV reinforce our confidence in the AMV platform\u2019s unique ability to deliver potent, long-lasting immune responses, making it an ideal candidate for advancing next-generation oncology therapies, particularly in HPV-induced cancers,\u201d <\/em>said Christophe Hubert, CEO of EnnoDC.<\/strong><\/p>\n

\u201cThese data establish a clinical proof-of-concept for AMVs in HIV, demonstrating the ability of our AMV studio to engage, prime and activate Dendritic Cells, in vivo, to drive a highly controlled and sustained immune response,\u201d <\/em>said Prof. Yves Levy, co-founder and Chief Scientific Officer of EnnoDC<\/strong>. \u201cThis is an important milestone, not only for our HIV program but for the broader application of AMVs in oncology, where we are actively advancing novel therapeutic options.\u201d<\/em><\/p>\n

Building momentum: positive Immuno-Oncology data at ESMO IO 2024<\/strong><\/p>\n

EnnoDC recently reported encouraging initial clinical data for its oncology AMV candidate CD40.HVac (AMV.HPVE6E7) at the 2024 ESMO Immuno-Oncology (IO) Congress. This novel class of immunotherapy, currently in a Phase 1\/2a trial for HPV-positive oropharyngeal cancer, demonstrated:<\/p>\n